Two-dose daclizumab regimen in simultaneous kidney-pancreas transplant recipients: Primary endpoint analysis of a multicenter, randomized study

Transplantation

Volumn 75, Issue 8, 2003, Pages 1260-1266

  Stratta, Robert J ^a   Alloway, Rita R ^b   Lo, Agnes ^c   Hodge, Ernest ^d  

^a WAKE FOREST BAPTIST HEALTH   (United States)

^b UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^d HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DACLIZUMAB; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS;

ACUTE GRAFT REJECTION; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PANCREAS TRANSPLANTATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PANCREAS; PANCREAS TRANSPLANTATION; SURVIVAL ANALYSIS;

EID: 0037469053     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000062838.38351.2A     Document Type: Conference Paper

References (27)

1. Gruessner AC, Sutherland DER. Analysis of pancreas transplant outcomes for United States cases reported to the United Network for Organ Sharing (UNOS) and non-US cases reported to the International Pancreas Transplant Registry (IPTR) In: Cecka JM, Terasaki PI, eds. Clinical transplants 1999. Los Angeles: UCLA Immunogenetics Center 2000, p 51-69.
2. Stratta RJ. Immunosuppression in pancreas transplantation: progress, problems and perspective. Transpl Immunol 1998; 6: 69.
3. Gruessner RWG. Antibody induction therapy in pancreas transplantation. Transplant Proc 1998; 30: 1556.
4. Beniaminovitz A, Itescu S, Lietz K, et al. Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with monoclonal antibody. N Engl J Med 2000; 342: 613.
5. Hengster P, Pescovitz MD, Hyatt D, et al. Cytomegalovirus infections after treatment with daclizumab, an anti IL-2 receptor antibody, for prevention of renal allograft rejection. Roche Study Group. Transplantation 1999; 68: 310.
6. Meulen CG, Riemsdijk IV, Hene RJ, et al. Two doses of daclizumab are sufficient for prolonged Il-2Rα-chain blockade. Am J Transplant 2001; 1: 276 (A 561).
7. Vincenti F, Kirkman R, Light S, et al. for the Daclizumab Triple Therapy Study Group. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med 1998; 338: 161.
8. Vincenti F, Lantz M, Birnbaum J, et al. A phase I trial of humanized anti-interleukin 2 receptor antibody in renal transplantation. Transplantation 1997; 63: 33.
9. Eckhoff DE, McGuire B, Sellers M, et al. The safety and efficacy of a two-dose daclizumab (Zenapax) induction therapy in liver transplant recipients. Transplantation 2000; 69: 1867.
10. Ahsan N, Holman MJ, Jarowenko MV, et al. Limited dose monoclonal IL-2R antibody induction protocol after primary kidney transplantation. Am J Transplant 2002; 2: 568.
11. Vincenti F, Lantz MV, Birnbaum JL, et al. Pharmacokinetic and pharmacodynamic studies of one or two doses of daclizumab in renal transplant patients. Am J Transplant 2001; 1: 385 (A 991).
12. Niemeyer G, Koch M, Light S, et al. Long-term safety, tolerability and efficacy of daclizumab (Zenapax) in a two-dose regimen in liver transplant recipients. Am J Transplant 2002; 2: 454.
13. Gaber AO, Gaber LW, Shokouh-Amiri MH, et al. Percutaneous biopsy of pancreas transplants. Transplantation 1992; 54: 548.
14. Nashan B, Light S, Hardie IR, et al. Reduction of acute renal allograft rejection by daclizumab. Daclizumab double therapy study group. Transplantation 1999; 67: 110.
15. Solez K, Axelsen RA, Benediksson H, et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 1993; 44: 411.
16. Papadimitriou JC, Drachenberg CB, Wiland A, et al. Histologic grading of acute allograft rejection in pancreas needle biopsy. Transplantation 1998; 66: 1741.
17. Bruce DS, Sollinger HW, Humar A, et al. Multicenter survey of daclizumab induction in simultaneous kidney-pancreas transplant recipients. Transplantation 2001; 72: 1637.
18. Bruce DS, Woodle ES, Newell KA, et al. Tacrolimus/mycophenolate mofetil provides superior immunosuppression relative to Neoral/mycophenolate in synchronous pancreas-kidney transplantation. Transplant Proc 1998; 30: 1538.
19. Burke GW, Ciancio G, Alejandro R, et al. Use of tacrolimus and mycophenolate mofetil for pancreas-kidney transplantation with or without OKT3 induction. Transplant Proc 1998; 30: 1544.
20. Corry RJ, Shapiro R, Egidi MF, et al. Pancreas transplantation without antibody therapy. Transplant Proc 1998; 30: 299.
21. Gruessner RWG, Sutherland DER, Drangstveit MF, et al. Mycophenolate mofetil and tacrolimus for induction and maintenance therapy after pancreas transplantation. Transplant Proc 1998; 30: 518.
22. Kaufman DB, Burke G, Bruce D, et al. The role of antibody induction in simultaneous pancreas kidney (SPK) transplant patients receiving tacrolimus and mycophenolate mofetil immunosuppression [abstract]. Transplantation 2000; 69: S206.
23. Kaufman DB, Leventhal JR, Koffron A, et al. Simultaneous pancreas-kidney transplantation in the mycophenolate mofetil/tacrolimus era: evolution from induction therapy with bladder drainage to noninduction therapy with enteric drainage. Surgery 2000; 128: 726.
24. Rasaiah SB, Light JA, Saski TM, et al. A comparison of daclizumab to ATGAM induction in simultaneous pancreas-kidney transplant recipients on triple maintenance immunosuppression. Clin Transplant 2000; 14: 409.
25. Golconda MS, Rayhill SC, Hunsicker LG. A low rate of acute rejection in simultaneous pancreas-kidney transplant recipients receiving daclizumab induction. [abstract]. Am J Transplant 2001; 1: 320 (A 737).
26. Van der Werf WJ, Reed AI, Hemming AW, et al. Two doses of daclizumab provides effective induction for simultaneous pancreas and kidney transplantation. Am J Transplant 2001; 1: 430 (A 1165).
27. Rehman LU, Atkinson RC, Minich PJ. Two dose daclizumab (Zenapax) is safe and effective induction therapy in adult renal transplantation. Am J Transplant 2001; 1: 300 (A 655).